|
CN111154736A
|
|
Process for the preparation of orlistat intermediates
|
|
CN110734420A
|
|
orlistat impurity F, preparation method and application thereof
|
|
CN110938006A
|
|
Preparation method of memantine hydrochloride impurity C
|
|
CN110963953A
|
|
Sulfaast tosilate process impurity I and preparation method and application thereof
|
|
CN110981771A
|
|
Preparation method and application of impurity E of suplatast tosilate process
|
|
CN110734443A
|
|
Preparation method of tadalafil-related substances I
|
|
CN110845493A
|
|
Preparation method of tropisetron hydrochloride
|
|
CN110317142A
|
|
A kind of preparation method of voglibose
|
|
CN110393708A
|
|
Solid orally ingestible and preparation method thereof containing Ropinirole
|
|
CN108743556A
|
|
A kind of Yi Dushaban tablets and preparation method thereof
|
|
CN107970225A
|
|
A kind of dabigatran etcxilate solid lipid nano granule and preparation method thereof
|
|
CN107935896A
|
|
The preparation method of Vortioxetine amino intermediate salt
|
|
CN107915685A
|
|
A kind of preparation method of hydrobromic acid Vortioxetine intermediate
|
|
CN108047131A
|
|
Doneppezil Hydrochloride impurity and its preparation method and application
|
|
CN107987053A
|
|
A kind of preparation method of high-purity Z-type Flupenthixol Hydrochloride
|
|
CN107935869A
|
|
Butanedioic acid desmethylvenlafaxine impurity and its preparation method and application
|
|
CN108409754A
|
|
The Preparation method and use of Yi Dushaban oxidative degradation impurity
|
|
CN107308154A
|
|
Treat or prevent pharmaceutical composition and its application of obesity and metabolic syndrome
|
|
CN107412196A
|
|
Orlistat nanoparticle and preparation method thereof and the application in antineoplastic
|
|
CN106943605A
|
|
Orlistat inclusion compound and preparation method thereof and the application in antineoplastic
|
